170 related articles for article (PubMed ID: 18757421)
1. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin.
Squarize CH; Castilho RM; Gutkind JS
Cancer Res; 2008 Sep; 68(17):7066-72. PubMed ID: 18757421
[TBL] [Abstract][Full Text] [Related]
2. Cowden's syndrome with immunodeficiency.
Browning MJ; Chandra A; Carbonaro V; Okkenhaug K; Barwell J
J Med Genet; 2015 Dec; 52(12):856-9. PubMed ID: 26246517
[TBL] [Abstract][Full Text] [Related]
3. Hamartoma-like lesions in the mouse retina: an animal model of
Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894
[No Abstract] [Full Text] [Related]
4. Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.
Boespflug A; Couraud S; Bringuier PP; Isaac S; Gérinière L; Perrot E; Edery P; Durieu I; Souquet PJ
Lung Cancer; 2013 Mar; 79(3):318-20. PubMed ID: 23261230
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal polyposis with esophageal polyposis is useful for early diagnosis of Cowden's disease.
Umemura K; Takagi S; Ishigaki Y; Iwabuchi M; Kuroki S; Kinouchi Y; Shimosegawa T
World J Gastroenterol; 2008 Oct; 14(37):5755-9. PubMed ID: 18837096
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin treatment for a child with germline PTEN mutation.
Marsh DJ; Trahair TN; Martin JL; Chee WY; Walker J; Kirk EP; Baxter RC; Marshall GM
Nat Clin Pract Oncol; 2008 Jun; 5(6):357-61. PubMed ID: 18431376
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in
Komiya T; Blumenthal GM; DeChowdhury R; Fioravanti S; Ballas MS; Morris J; Hornyak TJ; Wank S; Hewitt SM; Morrow B; Memmott RM; Rajan A; Dennis PA
Oncologist; 2019 Dec; 24(12):1510-e1265. PubMed ID: 31350329
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
9. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
Czerninski R; Amornphimoltham P; Patel V; Molinolo AA; Gutkind JS
Cancer Prev Res (Phila); 2009 Jan; 2(1):27-36. PubMed ID: 19139015
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
13. A family with PTEN mutations with malignancy and an unusually high number of offspring with autism spectrum disorder: a case report.
Gruhl SL; Sharma P; Han TS
J Med Case Rep; 2018 Nov; 12(1):353. PubMed ID: 30482242
[TBL] [Abstract][Full Text] [Related]
14. Mucocutaneous papillomatous papules in Cowden's syndrome.
Jornayvaz FR; Philippe J
Clin Exp Dermatol; 2008 Mar; 33(2):151-3. PubMed ID: 18021272
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing.
Clark RA; Pavlis M
J Invest Dermatol; 2009 Mar; 129(3):529-31. PubMed ID: 19209152
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.
Diegel CR; Cho KR; El-Naggar AK; Williams BO; Lindvall C
Cancer Res; 2010 Nov; 70(22):9143-52. PubMed ID: 21062985
[TBL] [Abstract][Full Text] [Related]
17. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
18. [Cowden syndrome, or multiple hamartomatous tumor syndrome, in clinical endocrinology].
Sardinoux M; Raingeard I; Bessis D; Coupier I; Renard E; Bringer J
Ann Endocrinol (Paris); 2010 Sep; 71(4):264-73. PubMed ID: 20627233
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
20. Diffuse esophageal glycogenic acanthosis: an endoscopic marker of Cowden's disease.
Kay PS; Soetikno RM; Mindelzun R; Young HS
Am J Gastroenterol; 1997 Jun; 92(6):1038-40. PubMed ID: 9177527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
